Company intelligence / Profile preview

Ototronix

Oak Ridge North, Texas, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

The MAXUM System, Ototronix's main product, is a minimally invasive middle ear implant for hearing loss. It is commercially available and is designed to provide significant improvements over conventional hearing aids, including enhanced clarity, reduced feedback, and minimized occlusion. No published clinical trial summaries are available, but patient testimonials and industry reviews indicate improved speech understanding and audibility compared to traditional devices.

Therapeutic areas: OtherNeurology
Modalities: Device
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Ototronix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ototronix.

Explore the full profile